[15]
Ibrahim, S.R.M.; Mohamed, G.A.; Elfaky, M.A.; Zayed, M.F.; El-Kholy, A.A.; Abdelmageed, O.H.; Ross, S.A. Mangostanaxanthone VII, a new cytotoxic xanthone from Garcinia mangostana. Z Naturforsch CJ Biosci. C, 2018, 73(5–6), 185-189.
[36]
Zhang, K.; Gu, Q.; Yang, K.; Ming, X.; Wang, J. Anticarcinogenic effects of α-mangostin: a review. Planta Med., 2017, 83(03/04), 188-202.
[51]
Wei, Z.; Zhaoxiang, Y.; Yunqi, G.; Xiaohui, G.; Liming, S.; Xujuan, Y. Mango leaf extract and application thereof. C.N. Patent 103768112A, 2014.
[52]
Charles, B.B.; Lai-ming, C.P.; Martin, P. Cancer treatment by combination therapy. U.S. Patent 7510830, 2009.
[60]
Abuzaid, A.S.; Iskandar, E.Y.; Kurniati, N.F.; Adanyana, I.K. Preventive effect on obesity of mangosteen (Garcinia mangostana L.) pericarp ethanolic extract by reduction of fatty acid synthase level in monosodium glutamate and high-calorie diet-induced male wistar rats. Asian J. Pharm. Clin. Res., 2016, 9(3), 257-260.
[77]
Leet, J.E.; Fairchild, C.R.; Mamber, S.W.; Xiaohong, L. Cytotoxic xanthone compounds. U.S. patent 20100311826A1, 2010.
[78]
Foulger, S. Skin care compositions containing xanthones. U.S. patent 11/474,084, 2007.
[100]
Pailee, P.; Kuhakarn, C.; Sangsuwan, C. Anti-HIV and cytotoxic biphenyls, benzophenones and xanthones from stems, leaves and twigs of Garcinia speciosa. Phytochemistry., 2018, 147, 68-79.
[114]
Beidou, Z. Application of 7-chloro-1, 3-dihydroxy xanthone in preparing antitumor drugs. C.N. Patent 108938620B, 2020.
[115]
Li, Ling A kind of xanthone compound, preparation method and application. C.N. Patent 109912623A, 2019.
[116]
Guoyong, L.; Liyu, H. New application of the Garcinia mangostana in terms for the treatment of FSGS medicine is prepared. C.N. Patent 106539843A, 2017.
[117]
Jingtao, Z.; Nan, H.; Zhenzhen, Y.; Yingping, Z. Application of the neomangiferin in vascular endothelial cell is protected. C.N. Patent 107397754A, 2017.
[118]
Li, C.; Yuying, L.; Xinxin, L.; Siyuan, W.; Qinying, L.; Miao, C.; Qinqing, Z. Application of iso-penicillium xanthone A from Penicillium oxalicum in aspect of melanoma. C.N. Patent 110922377A, 2020.
[119]
Hongxi, X.; Yuehoon, T.; Wenwei, F.; Zhchao, X.; Jiling, F.; Hongsheng, T. Garoliganthone C and its pharmaceutical composition and purposes. C.N. Patent 107382950A, 2017.
[120]
Ling, L.; Zhihong, Z.; Yanfen, N.; Lihu, G.; Hua, L.; Qiang, L. The new application of α-mangostin prevention hyperuricemia and gout. C.N. Patent 108785300A, 2018.
[121]
Hongxi, X.; Wenwei, F.; Rong, W.; Baojun, Z.; Jinling, Y.; Zhijun, S.; Hongsheng, T. A kind of medicinal usage of xanthones compound A. C.N. Patent 108272790A, 2018.
[122]
Beidou, Z.; Xiaojing, P.; Menghan, H. Application of -1,3 dihydroxy xanthone of 7- Nitros in terms of preparing antitumor drug. C.N. Patent 108619132A, 2018.
[123]
Idowu, O.C. Mangiferin as a protective agent against mitochondrial DNA damage and skin-care compositions comprising same. W.O. Patent 2019150087A1, 2019.
[124]
Yingyin, S.; Wan, H. Mangiferin treats or prevents the application in drug induccd acute liver damage drug in preparation. C.N. Patent 109331010A, 2019.
[125]
Berk, M.; Wendy, L. Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders. A.U. Patent 2015222697A1, 2016.
[126]
Li, X.; Liang, J. Medicine with blood pressure reducing effect and production method of medicine. C.N. Patent 104873488A, 2015.